CORT Revenue of $256.1 million, a 32 percent increase over the same period in 2025 Korlym® and authorized generic product revenue of $20

CORT Revenue of $256.1 million, a 32 percent increase over the same period in 2025 Korlym® and authorized generic product revenue of $208.6 million Lifyorli™ product revenue of $47.6 million Increase in 2026 revenue guidance to $1.1 — $1.2 billion Net income of $43.0 million, compared to $35.1 million in second quarter 2025 Cash and investments of $544.6 million at June 30, 2026